The mechanism of CD4 ؉ T-cell depletion during chronic human immunodeficiency virus type 1 (HIV-1) infection remains unknown. Many studies suggest a significant role for chronic CD4 ؉ T-cell activation. We assumed that the pathogenic process of excessive CD4 
Human immunodeficiency virus type 1 (HIV-1) is the etiologic agent of AIDS, which is a manifestation of the progressive CD4
ϩ T-cell depletion that occurs in the setting of HIV-1 infection (19, 59) . During acute infection by HIV-1, the process of CD4 ϩ T-cell depletion is initiated by unchecked viral replication that occurs before an adaptive immune response is mounted (9, 19, 21, 45, 51, 59, 71, 77) . Concomitant with development of a cytotoxic T-lymphocyte (CTL) response and the consequent reduction in viral replication, however, the CD4 count rebounds to a quasi-steady-state level that is below the baseline CD4 count of HIV-negative (HIV Ϫ ) individuals and that decreases on the time scale of years (19, 59 ). In the gut-associated lymphoid tissue, where the majority of the body's lymphocytes reside, there is a dramatic depletion of CD4 ϩ T cells during acute infection (9, 45, 51, 71, 77) . However, AIDS develops only when CD4 ϩ T cells have been sufficiently depleted that opportunistic infections occur (reflected by a CD4 count below 200 cells/l). It is unclear how and why CD4 ϩ T cells are depleted in the setting of chronic HIV-1 infection (19, 25, 28, 50, 59) .
The "tap and drain" model of CD4 ϩ depletion during HIV-1 infection developed by Ho and colleagues suggests that the rate of CD4 ϩ T-cell destruction by HIV-1 during chronic infection is too fast to be compensated for by natural CD4 ϩ T-cell production (34) . Consistent with the idea of increased destruction, CD4 ϩ T cells from simian immunodeficiency virus (SIV)-infected macaques have been shown to have a substantially higher turnover rate than CD4 ϩ T cells from uninfected macaques (30, 41, 52, 65) . While more-recent studies continue to indicate a role for viral destruction (56) in CD4 ϩ T-cell depletion, several important experimental observations suggest that factors in addition to destruction by viral infection are responsible for CD4 ϩ T-cell depletion in the setting of HIV-1 infection. In particular, in both SIV-infected macaques and HIV-1-infected individuals, the majority of apoptotic CD4 ϩ T cells are "bystander" cells rather than productively infected cells (20) . Furthermore, the frequency of HIV-1-infected CD4 ϩ T cells in humans is, on average, very low (14) and likely is too low if virus-induced death subsequent to infection is solely responsible for HIV-1-mediated CD4 ϩ T-cell depletion (20) , given known parameters of CD4 ϩ T-cell dynamics in the setting of HIV-1 infection (2). Consistent with this observation, natural hosts of SIV, such as the sooty mangabey or African green monkey, do not exhibit a dramatic decline in the number of CD4 ϩ T cells despite high viral loads similar to those observed in AIDS-susceptible nonhuman primate species, such as the rhesus macaque (38, 70) .
Chronic HIV-1 infection is characterized by massive and chronic activation of CD4 ϩ T cells (29, 41, 63) . This activation is reduced to near-normal levels by treatment with highly active antiretroviral therapy (HAART) (29) or in long-term nonprogressors (13) . Interestingly, the level of CD4 ϩ T-cell activation correlates better than the viral load with the degree of reduction in CD4 count in both HIV-1-and HIV-2-infected individuals (43, 54, 74) . As with HIV-1, SIV induces excessive CD4 ϩ T-cell activation in AIDS-susceptible species of nonhuman primates (e.g., rhesus macaques) but not in its natural hosts (e.g., the sooty mangabey or African green monkey) (70) . These studies strongly suggest that massive and chronic CD4 ϩ T-cell activation induced by HIV-1 infection plays a role in CD4 ϩ T-cell depletion (25, 28, 50) . However, several important questions remain unanswered. In particular, what is the mechanism through which chronic CD4 ϩ T-cell activation leads to CD4 ϩ T-cell depletion? Furthermore, what signals are acting on CD4 ϩ T cells in the setting of HIV-1 infection (i) to induce such a substantial increase in activated CD4
ϩ T cells and (ii) to modulate CD4 ϩ T-cell depletion? In the present report, we describe a novel approach aimed at elucidating the molecular mechanisms through which chronic CD4 ϩ T-cell activation in the setting of HIV-1 infection leads to CD4
ϩ T-cell depletion. We hypothesized that if chronic CD4 ϩ T-cell activation contributes to CD4 ϩ T-cell depletion, then this pathogenic process should be reflected at the molecular level in the transcriptional profiles of activated CD4 ϩ T cells of chronically infected HIV-positive (HIV ϩ ) individuals. Specifically, we wanted to determine whether there were qualitative differences in the activated CD4 ϩ T cells from HIV-1-infected individuals compared to the activated CD4 ϩ T cells from uninfected individuals. With this idea in mind, we carried out a microarray study of the gene expression profiles of activated CD4 ϩ T cells from untreated, chronically infected HIV ϩ individuals with a comparison to activated CD4 ϩ T cells from healthy HIV Ϫ individuals. We observed dramatic differences in patterns of gene expression in activated CD4 ϩ T cells from infected versus uninfected individuals that lead to a new model for the role of chronic CD4 ϩ T-cell activation in CD4 ϩ T-cell depletion in the setting of HIV-1 infection.
MATERIALS AND METHODS

Study subjects. Seventeen HIV
Ϫ donors and 28 HIV ϩ donors (21 untreated and viremic and 7 treated and aviremic; unpublished data) were enrolled in this study after signed, informed consent approved by the Johns Hopkins Medical Institutions Institutional Review Board was obtained. Inclusion criteria for viremic HIV ϩ donors were as follows: (i) lack of prior antiretroviral therapy or lack of antiretroviral therapy for more than 1 year prior to study entry and (ii) viremia of Ͼ1,000 copies/ml for more than 1 year, as well as (iii) CD4 count of Ͼ200 cells/l (in order to ensure that enough CD4 ϩ T cells could be isolated for experiments). Inclusion criteria for aviremic HIV ϩ donors were as follows: (i) on HAART for more than 1 year, (ii) suppression of viremia to Ͻ50 copies/ml for more than 1 year, and (iii) CD4 count of Ͼ200 cells/l (in order to ensure that enough CD4
ϩ T cells could be isolated for experiments). Exclusion criteria for all blood donors were as follows: (i) chronic hepatitis B or hepatitis C infection and (ii) AIDS defining illness within 1 year of blood draw.
Cell isolation. CD4 ϩ T cells were positively selected to Ͼ98% purity from freshly isolated peripheral blood mononuclear cells, using magnetic microbeads and subsequent column purification according to the manufacturer's protocol (Miltenyi Biotec, Auburn, CA). Activated CD4 ϩ T cells were similarly isolated by positive selection from CD4 ϩ T cells using CD25 microbeads (Miltenyi Biotec, Auburn, CA). In order to ensure isolation of CD25 lo cells, the manufacturer's protocol was altered such that 2 l of CD25 microbeads and 8 l of wash medium (phosphate-buffered saline [pH 7.2 to 7.4], 2% newborn calf serum, 0.1% glucose, 1% penicillin/streptomycin, 12 mM HEPES [pH 7.2]) were used per million CD4 ϩ T cells. The purity of isolated CD25 ϩ cells was almost always greater than 95%.
Microarray. Total RNA was isolated from cells using the RNeasy minikit (Qiagen). RNA from control and experimental tissue was processed using the two-round RNA amplification protocol described by Affymetrix (Affymetrix GeneChip eukaryotic small-sample target labeling assay, version II). Briefly, 100 ng of total RNA was used to synthesize first-strand cDNA, using the SuperScript Choice system (Invitrogen, Carlsbad, CA). The 24 oligo(dT)-plus-T7 promoter was used as a primer (Proligo LLC, Boulder, CO). Following double-strandedcDNA synthesis, the product was purified by phenol-chloroform extraction and unlabeled ribonucleotides were used in a first round of in vitro transcription cRNA amplification (MegaScript, Ambion, Austin, TX). The following cycle of cDNA synthesis was started with random primers, and the oligo(dT)-with-T7 promoter was again used as a primer at the second-strand cDNA synthesis step. The double-stranded cDNA product was then purified again by phenol-chloroform extraction. Consequently, biotinylated antisense cRNA was generated through in vitro transcription using the BioArray RNA high-yield transcript labeling Kit (ENZO Life Sciences Inc., Farmingdale, NY). Fifteen micrograms of the biotinylated labeled cRNA was fragmented at 94°C for 35 min (100 mM Tris-acetate, pH 8.2, 500 mM potassium acetate, 150 mM magnesium acetate), and 10 g of total fragmented cRNA was hybridized to the Affymetrix Human Genome GeneChip array U133Plus 2.0 for 16 h at 45°C with constant rotation (60 rpm). The Affymetrix Fluidics Station 450 was then used to wash and stain the chips, removing the nonhybridized target and incubating with a streptavidinphycoerythrin (PE) conjugate to stain the biotinylated cRNA. The staining was then amplified using goat immunoglobulin G (IgG) as a blocking reagent and biotinylated antistreptavidin antibody (goat), followed by a second staining step with a streptavidin-PE conjugate. Fluorescence was detected using the Affymetrix-GS3000 GeneArray scanner, and image analysis of each GeneChip was done through the GeneChip Operating System software from Affymetrix (GCOS1.3), using the standard default settings. For a comparison between different chips, global scaling was used, scaling all arrays to a user-defined target intensity of 150.
Microarray analysis. The quality of the microarray experiment was assessed with affyPLM and Affy, two BioConductor packages for statistical analysis of microarray data. To estimate the gene expression signals, data analysis was conducted with the chips' CEL file probe signal values at the Affymetrix probe pair (perfect match probe and mismatch probe) level using the statistical algorithm RMA (robust multiarray expression measure) (37) with Affy. This probelevel data processing includes a normalization procedure utilizing a quantile normalization method (7) to reduce the obscuring variation between microarrays which might be introduced during the processes of sample preparation, manufacture, fluorescence labeling, hybridization, and/or scanning. With these signal estimates, principal component analysis and multidimensional scaling analyses were performed using the R software program to assess sample variability. The quality assessment, principal component analysis, and multidimensional scaling analysis identified and disqualified a discordant control sample chip, C9.
With the signal data in a log-transformed format, differential gene expression between controls and HIV ϩ patients was also assessed by statistical linear model analysis using the BioConductor package limma, in which an empirical Bayes method is used to moderate the standard errors of the estimated log-fold changes of gene expression, resulting in more-stable inference and improved power, especially for experiments with small numbers of microarrays (www.bioconductor .org) (72) . The moderated t-statistic P values derived from the linear-model analysis described above were further adjusted for multiple testing by Benjamini and Hochberg's method to control the false discovery rate (FDR). The FDR was used to obtain the list of differentially expressed genes.
All Bioconductor packages are available at http://www.bioconductor.org. All computation was performed using the R software program (http://www.r-project .org) (36), a highly extensible language and environment that provides a wide variety of statistical (linear and nonlinear modeling, classical statistical tests, time-series analysis, classification, clustering, etc.) and graphical techniques.
We performed hierarchical clustering, gene ontology analysis, and graphical representation (volcano plots) using the Spotfire analytic platform with its DecisionSite for Functional Genomics extension. All Affymetrix expression data from the 20 retained chips, representing 11 HIV ϩ specimens and 9 HIV Ϫ controls, had been previously normalized by RMA, as described above, before data were imported into Spotfire.
Hierarchical clustering was performed on a subset of 3,742 probe sets, representing 2,669 genes, that were determined to be significantly differentially expressed at a threshold of an FDR of Յ0.01. The pairwise clustering algorithm employed the unweighted pair-group method with arithmetic mean method and defined the similarity between clusters by their Pearson's r correlation. This measure rewards positive correlation, i.e., the most similar expression profiles in terms of both the magnitude and direction of changes. Both probe sets (rows) and chips (columns) were blindly clustered, with the final order determined by average values and not by input order.
We analyzed gene functionality by employing the classifications and vocabulary of the Gene Ontology Consortium (GO) (4) . The GO project annotates the function and cellular localization of gene products based on evidence from manual literature-based annotation, structural or sequence similarity, and/or computational analysis, and every GO annotation contains both evidence and source attribution. Since GO annotates gene products, i.e., proteins, it is neces-VOL. 82 (48), an online database of 533 position weight matrices (an algorithm for scoring DNA sequence to identify a particular motif, in this case a TF binding site) for TF sites and scanned for TF binding sites using the program MATCH v10.4 with the settings "group of matrices" set to "vertebrates," with "high quality matrices" selected. Our analysis was performed five separate ways for "cutoff selection," set to "minimize false positives" and "minimize the sum of both error rates," with "mat. sim." and "core sim." set (respectively) to 0.8 and 0.85, 0.9 and 0.9, and 0.95 and 0.95. Analysis for enrichment of TF binding sites was performed with P values calculated using a simple binomial test, and Q values were calculated (significance taken to be a Q value of Ͻ0.1) to correct for the FDR, exactly as previously described (62) .
We repeated our analysis by defining promoters as the 1.5-kb or 2-kb sequences upstream of each gene and found no qualitative differences.
Flow cytometry. Freshly isolated CD4 ϩ T cells were resuspended in wash medium (10 6 to 2 ϫ 10 6 cells in 100 l). Cells were incubated with antibodies to cell surface markers on ice for 25 min. The following antibodies were used for surface staining of cells: PE-conjugated anti-CD25, PE anti-HLA-DR, PE mouse IgG1 isotype, PE mouse IgG2a isotype, and fluorescein isothiocyanate (FITC)-conjugated CD4.
For intracellular staining after we stained for the appropriate extracellular markers, cells were fixed and permeabilized with 50% ethanol overnight at Ϫ20°C. The following antibodies were used for intracellular staining as previously described (23): FITC cyclin A (clone BF683) and FITC cyclin B 1 (clone GNS-1). 7-Aminoactinomycin was used to stain DNA. All antibodies and 7-aminoactinomycin were purchased from BD Biosciences. Data were collected by routinely acquiring Ͼ300,000 total events (based on forward-and side-scatter properties) with BD FACScalibur and CellQuest software. Fluorescence-activated cell sorting data were analyzed with CellQuest. P values were calculated using Welch's t test, comparing HIV ϩ samples to HIV Ϫ samples. Microarray data accession number. All microarray results have been deposited in the Gene Expression Omnibus database (accession number GSE9927).
RESULTS
Microarray analysis of in vivo-activated CD4
؉ T cells. All individuals, regardless of their HIV status, have activated CD4
ϩ T cells in their peripheral blood and in secondary lymphoid and peripheral tissues. However, HIV Ϫ individuals do not exhibit depletion of CD4 ϩ T cells. If chronic activation of CD4 ϩ T cells in the setting of HIV-1 infection drives a pathogenic process, then activated CD4 ϩ T cells from untreated, HIV ϩ individuals should reflect this process. To gain insight into the changes that may arise in activated CD4 ϩ T cells in the setting of HIV-1 infection, we performed a microarray study of transcriptional differences between activated CD4 ϩ T cells from HIV ϩ and HIV Ϫ individuals. To gain the clearest understanding of transcriptional changes induced by chronic HIV-1 infection, we used strict inclusion criteria for both HIV ϩ and HIV Ϫ blood donors. HIV ϩ donors used for our microarray study met the following criteria: (i) lack of prior antiretroviral therapy or lack of antiretroviral therapy for more than 1 year prior to study entry, (ii) HIV ϩ viremia of Ͼ1,000 copies/ml for more than 1 year, and (iii) CD4 count of Ͼ200 cells/l. Exclusion criteria for HIV ϩ donors were as follows: (i) chronic hepatitis B or hepatitis C infection and (ii) AIDS defining illness within 1 year of blood draw. For our microarray study, blood donors were also chosen to closely age match the HIV ϩ cohort with the HIV Ϫ cohort in order to avoid any confounding effects of age on immune function.
Furthermore, the transcriptional state of an activated CD4 ϩ T cell is dynamic and changes with time, beginning at the initial activation event (76) . Activated CD4 ϩ T cells in the peripheral blood include cells that were activated over a wide temporal spectrum. In order to minimize the confounding effects of different temporal distributions of activated CD4 ϩ T cells between the patient populations, we used CD25 as our marker of activation. CD25, the alpha chain of the interleukin 2 (IL-2) receptor, is up-regulated within 2 days of activation and is down-regulated several days later (16) . Therefore, CD4 ϩ
CD25
ϩ T cells represent a temporally discrete and relatively homogeneous population of activated CD4 ϩ T cells. Although high-level expression of CD25 has also been used as a marker of regulatory T cells (Tregs), Tregs compose a very small fraction of the total activated CD4 ϩ CD25 ϩ T-cell population in human subjects (Ͻ5% in mice and considerably less in humans [61] ). Additionally, by taking additional steps in cell purification to isolate all CD4 ϩ CD25 ϩ cells rather than just CD4 ϩ CD25 hi cells, we enriched for activated CD4 ϩ CD25 ϩ cells and reduced the contribution of these Tregs to our study. Finally, the results of our analyses do not show differential expression of any Treg-specific markers, such as FOXP3, CTLA4, and GITR, which strongly suggests that differential Treg composition of CD4 ϩ CD25 ϩ T cells from HIV Ϫ and untreated HIV ϩ individuals did not contribute to our observed results. Therefore, the contribution of these Tregs to our overall results is most likely insignificant. For our microarray study, we used Affymetrix U133Plus 2.0 GeneChips, which probe for 54,630 different transcripts, representing 20,254 different Entrez genes. Raw microarray signals were preprocessed using the RMA method and analyzed to obtain P values for each probe set, with corresponding FDRs, from which we generated our list of differentially expressed genes.
The results of the microarray study demonstrated that clear transcriptional differences exist between the CD4 ϩ CD25 ϩ T cells of HIV ϩ individuals and those of HIV Ϫ individuals (Fig.  1A) . For a 1% FDR, analysis of microarray results yielded 2,110 transcripts that were 1.10-to 2.85-fold down-regulated and 1,633 transcripts that were 1.09-to 8.33-fold up-regulated in the CD4 ϩ CD25 ϩ T cells of chronically infected, untreated HIV ϩ individuals (Fig. 1B) . When categorized with respect to the change in expression, the number of transcripts that were differentially expressed in CD4 ϩ CD25 ϩ T cells from HIV change. This was true for both down-and up-regulated genes, but the transcripts showing the largest change (ranging from 3-to 8.33-fold differentially expressed) were transcripts that were all up-regulated in CD4 ϩ CD25 ϩ T cells from HIV ϩ versus HIV Ϫ individuals (Fig. 1B) . There was no difference in CD25 expression between the HIV Ϫ and untreated HIV ϩ individuals, confirming that the purified cells were relatively homogeneous with respect to this activation marker. Genes that were differentially expressed in the activated CD4 ϩ T cells of HIV ϩ individuals compared to expression for HIV Ϫ individuals belong to many different gene categories, including those involving the cell cycle, growth, cytokine responses, apoptosis, and survival, as well as metabolic genes (all with an unadjusted P value of Ͻ10 Ϫ8 according to gene ontology [75] ). Quite strikingly, the most highly up-regulated transcripts could almost entirely be categorized as related to the cell cycle or interferon signaling. As is discussed below, of the differentially expressed genes, cell cycle genes and interferon-stimulated genes stood out with respect to consistency of differential expression, number of differentially expressed genes, and overall change.
Cell cycle genes are up-regulated in untreated HIV ؉ patients. Based on gene ontology annotations, we found 255 (out of 3,742 total) differentially expressed transcripts that were classified as involved in the cell cycle (without including transcripts of genes directly involved in signal transduction pathways) (unpublished data). Of these, 190 (out of 1,632 total) were up-regulated, while only 65 (out of 2,110 total) were down-regulated ( Fig. 2A) .
The 190 up-regulated transcripts represented 150 different genes. These genes include regulators of the cell cycle as well as cell cycle-regulated genes (genes whose temporal expression is regulated by the cell cycle). Transcription of cell cycle-reg- (55) . Interestingly, these are genes whose transcription is associated specifically with entry into the cell cycle from quiescence or G 0 .
We observed 65 cell cycle-associated transcripts, representing 52 different genes, to be down-regulated from ϳ1.2-to 2.5-fold in CD4 ϩ CD25 ϩ cells from HIV ϩ individuals compared to results for HIV Ϫ individuals. For some of these genes, the mechanistic link to the cell cycle is unclear (including the most highly down-regulated cell cycle-associated gene-the septin 10 gene [SEPT10]). Of the other down-regulated transcripts categorized as cell cycle related, most are known negative regulators of the cell cycle (or proliferation), such as that encoding cyclin L 2 (CCLN2), HEXIM2, LZTS1, GADD45B, TSC1, and TUSC4, or mediators of cell cycle arrest, such as HBP1 and the sestrin 1 gene (SESN1). Interestingly, two cell cycle genes (MDM4 and RB1CC1) that we have identified to be down-regulated in CD4 ϩ CD25 ϩ T cells of HIV ϩ individuals are also known to be associated with cellular quiescence and the G 0 phase of the cell cycle.
Interferon-related genes are up-regulated in untreated HIV ؉ patients. The other major category of highly up-regulated transcripts in CD4 ϩ CD25 ϩ cells from HIV ϩ individuals compared to cells from HIV Ϫ individuals comprises interferonstimulated genes. Importantly, almost all of the differentially expressed, interferon-stimulated transcripts were up-regulated rather than down-regulated (Fig. 2B) . We found 94 up-regulated interferon-stimulated transcripts (from 1.13-to 8.33-fold), including those known to be up-regulated in response to type I interferons (e.g., alpha interferon and beta interferon), type II interferons (i.e., gamma interferon), or type I and II interferons (unpublished data). An extensive literature search revealed that the majority of interferon-stimulated genes upregulated in CD4 differentiation (1, 33) . The up-regulation of these genes is consistent with previously published reports of a T H 1 skewed immune response during chronic HIV-1 infection (15) and may be due to induction by type I interferons (33) . These findings suggest that CD4 ϩ T cells in untreated HIV ϩ individuals are activated in the presence of type I interferons.
Apoptosis-regulating genes are not differentially expressed in a consistent pattern in activated CD4 ؉ T cells from HIV ؉ versus HIV ؊ donors. Interestingly, 93 of the differentially expressed transcripts (unpublished data), representing 68 different genes, were categorized by gene ontology as "induction of programmed cell death" and "negative regulation of programmed cell death" (Fig. 2C) . However, there was no clear pattern suggesting a pro-or antiapoptotic phenotype. Of the differentially expressed apoptosis-related transcripts, 37 are negative regulators of apoptosis. Of these, 22 transcripts, including those of BIRC5/survivin, PIM2, and MYBL2, were up-regulated, while 15 transcripts including those for c-Myc (MYC), apoptosis inhibitor 5 (API5), and BIRC1 (NAIP), were down-regulated. We identified 61 differentially expressed transcripts that are considered to be inducers of programmed cell death. Of these, 32 transcripts, including those of BID, the BAK gene (BAK1), the p53 gene (TP53), the caspase 3 gene (CASP3), the caspase 7 gene (CASP7), and CD38 were upregulated, while 24 transcripts, including PDCD5, PDCD6, FOXO3, and BCLAF1, were down-regulated.
Interestingly, the majority of these differentially expressed, apoptosis-related transcripts demonstrated small changes in CD4 ϩ CD25 ϩ T cells from HIV ϩ individuals compared to results for HIV Ϫ individuals. Furthermore, there is no obvious directionality of differential gene expression for either negative regulators or positive inducers of programmed cell death. This is clear from the intermingling of both groups of differentially expressed transcripts on the volcano plot (Fig.  2C) . Therefore, the observed transcriptional changes do not suggest an obvious trend toward either increased apoptosis/ decreased survival or decreased apoptosis/increased survival in CD4
ϩ CD25 ϩ T cells from HIV ϩ individuals compared to results for HIV Ϫ individuals. Enrichment of proliferative and interferon signaling-related TF binding sites in the promoters of up-regulated genes. Having characterized the major differences in gene expression between activated CD4 ϩ T cells from untreated HIV ϩ individuals and those from HIV Ϫ individuals, we sought to understand the proximal causes of these differences. We assumed that differential expression of sets of genes was the result of differential activation of transcriptional programs regulated by specific TFs. We hypothesized that the promoters of differentially expressed genes would be enriched in binding sites of TFs that are differentially activated in CD4 ϩ CD25 ϩ T cells from untreated HIV ϩ individuals compared to those from HIV Ϫ individuals. From an enrichment of TF binding sites, we could potentially trace the signals that drive the observed differences between activated CD4 ϩ T cells from untreated HIV ϩ individuals and those from HIV Ϫ individuals. To determine whether particular TF binding sites were enriched in the promoters of genes that were differentially expressed between CD4 ϩ CD25 ϩ T cells from untreated HIV ϩ individuals compared to those from HIV Ϫ individuals, we performed a variation of a previously described promoter analysis (62) . This method of analysis was previously used to predict activated TFs and signaling pathways in various cancers and to predict E2F-regulated transcripts (62) . We used TRANSFAC Professional (48), a database of 533 position weight matrices for TF binding sites, to analyze the promoter (defined as 1 kb upstream of the start transcription site) of each transcript represented on the Affymetrix U133Plus 2.0 GeneChip with the program MATCH (39) . For robustness, we performed our analysis with only high-quality position weight matrices in TRANSFAC and for five different core and matrix similarity score cutoffs (described in Materials and Methods) in MATCH. Having defined regulatory signatures (the set of all promoters that contain at least one binding site specified by a particular high-quality position weight matrix) for each TF binding site on the background of the U133Plus 2.0 GeneChip, we used a simple binomial test with an FDR (calculated as a Q value) cutoff of 0.10 to deter- (Fig. 3) . We found that TF binding sites related to proliferation, in particular, binding sites for E2F-mediated transcription (e.g., general E2F family, E2F1, E2F1/DP2 dimer, and E2F1/ DP1/Rb complex), as well as CREB/ATF-mediated transcription (general CREB family, general ATF family, CREBP1/cJun dimer, and CREBP1), were enriched in the promoters of all differentially expressed transcripts (Fig. 3) . This is consistent with these TFs having dual roles as transcriptional activators and repressors during proliferation (49, 55) . Interestingly, we found a small cluster of ATF family member and CREB family binding sites that are enriched in only the promoters of transcripts that are down-regulated in CD4 ϩ CD25 ϩ T cells from untreated HIV ϩ individuals compared to those from HIV Ϫ individuals (Fig. 3) , which suggests that these TFs may be involved with down-regulation of certain genes in activated CD4 ϩ T cells during HIV infection. However, because we found other binding sites for these same TFs enriched in the promoters of up-regulated transcripts (within the same cluster as E2F family members), it may be that other factors are regulating the binding of CREB and ATF family members at binding sites in the promoters of down-regulated transcripts (26) . interferon signaling, including IRF7, ISRE, and STAT family members (Fig. 3) . These findings are consistent with the most dramatic transcriptional changes that we identified in our microarray study, i.e., cell cycle-related and type I-stimulated transcripts. Furthermore, these results suggest that active processes, involving type I interferon signaling and proliferative stimuli, are mediating the transcriptional changes in CD4 ϩ
ϩ T cells of untreated HIV ϩ individuals compared to those of HIV Ϫ individuals. These results confirm our gene expression results that cell cycle-associated and type I interferon-stimulated genes comprise the most highly up-regulated genes in CD4 ϩ CD25 ϩ T cells of untreated HIV ϩ individuals compared to results for HIV Ϫ individuals.
Cell cycle distribution and protein expression in in vivoactivated CD4
؉ T cells from HIV ؉ individuals corroborate gene expression profiling and promoter analysis. To test whether our transcript-level microarray findings reflect functional effects in vivo, we studied cell cycle parameters in CD4 ϩ T cells activated in vivo from HIV Ϫ donors, from untreated chronically infected HIV ϩ patients, and from HIV ϩ patients on HAART. Using flow cytometry, we measured the expression of cyclin A (CCNA2) and cyclin B 1 (CCNB1), whose two corresponding genes we have found to be up-regulated in CD4 ϩ CD25 ϩ cells from untreated HIV ϩ individuals, at the protein level in relation to cell cycle phase (reflected by a flow cytometric measurement of DNA quantity). Cyclin A is upregulated late in G 1 and begins to accumulate in the S phase of the cell cycle, mostly due to the action of E2F TFs. Interacting with both CDK2 and CDC2, cyclin A functions in both the S and G 2 /M phases of the cell cycle (79) . Cyclin B 1 is up-regulated late in S phase and accumulates through the G 2 /M phase of the cell cycle, due in part to regulatory effects of cyclin A, and is a critical component of the mitosis promoting factor complex (40) . Cyclins A and B are both degraded during mitosis.
We found that a significantly larger fraction of CD4 
CD25
ϩ cells from untreated HIV ϩ individuals. This shift was much less prominent for patients on HAART (Fig. 4B) . In order to check whether these cell cycle findings were specific to CD4 ϩ CD25 ϩ T cells, we examined activated CD4 ϩ T cells using a different activation marker: HLA-DR, which is upregulated later than CD25 during the process of activation. We found an increase in the frequency of cells expressing cyclin A and/or cyclin B 1 among CD4 ϩ T cells positive for the late activation marker HLA-DR ϩ for untreated HIV ϩ individuals similar to that for HIV Ϫ individuals (Fig. 5A ). This increase was much less prominent for patients on HAART. As expected, we also found a shift toward post-G 0 /G 1 phases in the cell cycle distribution of CD4 ϩ HLA-DR ϩ cells from untreated HIV ϩ individuals (Fig. 5B) . This shift was also much less prominent for patients on HAART. Interestingly, we found that the percentages of cells expressing cyclin A and cyclin B 1 were much higher among CD4 ϩ CD25 ϩ T cells from untreated HIV ϩ individuals than among CD4 ϩ HLA-DR or cyclin A/B 1 -expressing activated CD4 ϩ T cells in our study is low, these results are consistent with previous measurements of these parameters in CD4 ϩ T cells from the peripheral blood, where cycling cells are much less common than in peripheral lymphoid organs (69) . However, these results most likely reflect the state of activated CD4 ϩ T cells in the lymph nodes of HIV ϩ individuals compared to those of HIV Ϫ individuals qualitatively, if not quantitatively.
Finally, because we simultaneously measured CD25 and cyclin expression, as well as DNA content, in freshly isolated CD4 ϩ T cells, we were able to examine the temporal pattern of cyclin expression. We found that cyclin A and cyclin B 1 were expressed at appropriate phases of the cell cycle in CD4 ϩ T cells activated in vivo from untreated HIV ϩ individuals. Indeed, the temporal pattern of cyclin A and cyclin B 1 protein expression in CD4 ϩ CD25 ϩ T cells of untreated HIV ϩ individuals was not different from expression in CD4 ϩ CD25 ϩ T cells of HIV Ϫ individuals or phytohemagglutinin (PHA)-activated CD4 ϩ T cells (Fig. 6) . Specifically, we observe that in all samples, cyclin A expression increases from late G 1 phase to the G 2 /M phases while cyclin B 1 expression increases from S phase to the G 2 /M phases. We also observed appropriate temporal expression patterns for cyclin A and cyclin B 1 in CD4 ϩ HLA-DR ϩ T cells of untreated HIV ϩ individuals (data not shown).
DISCUSSION
A preponderance of data now support the hypothesis that chronic CD4 ϩ T-cell activation plays a role in CD4 ϩ T-cell depletion during HIV-1 infection (13, 22, 25, 28, 29, 41, 43, 50, 52, 54, 63, 65, 74) . Despite numerous suggestive and correlative studies, a mechanism for the effect of chronic CD4 ϩ T-cell activation on CD4 depletion has not yet been established. Proposed mechanisms include accelerated CD4 ϩ T-cell senescence (3, 25, 34, 52, 63, 65) , CD4
ϩ T-cell exhaustion (25, 28, 34, 52, 63, 65), and activation-induced cell death (18, 22, 24, 25) . In this study, we present results that support a novel mechanism for the role of chronic CD4 ϩ T-cell activation in CD4 ϩ T-cell depletion. Our approach was based on the assumption that the pathogenic process leading to chronic CD4 ϩ T-cell activation would be reflected by transcriptional changes in CD4 ϩ T cells activated in vivo. We studied and compared in vivo-activated CD4 ϩ T cells from untreated HIV ϩ individuals to in vivo-activated CD4 ϩ T cells from healthy individuals. Using transcriptional profiling and analysis of the promoters of differentially expressed genes together with functional cell cycle analysis, we show that activated CD4 ϩ T cells in untreated HIV ϩ individuals are in a hyperproliferative state under the influence of type I interferons. The power of our approach and our ability to see such clear differences is largely a result of our focus on a homogeneous population of activated CD4 ϩ
CD25
ϩ T cells, rather than total CD4 ϩ T cells, which are a heterogeneous population of cells, the composition of which varies from person to person. Because of the relatively small fraction of CD4 ϩ CD25 ϩ T cells that are Tregs and our experimental steps to enrich for activated CD4 ϩ CD25 ϩ T cells, as well as the fact that we did not observe differential Tregspecific gene expression (e.g., FOXP3, CTLA4, and GITR), we believe that our results reflect true transcriptional differences between activated CD4 ϩ CD25 ϩ T cells from untreated HIV Many previous studies have demonstrated increases in apoptotic markers, such as Fas and FasL, on total CD4
ϩ T cells in HIV-1 infection (18, 24, 54) . These increases correlated with increased CD4
ϩ T-cell activation (18, 24, 54) , suggesting a mechanism for HIV-induced CD4 ϩ T-cell depletion. However, in focusing on a relatively homogeneous population of cells, we observed only a modest increase in the transcription of some apoptotic genes in activated CD4 ϩ T cells from HIV ϩ individuals compared to results for HIV Ϫ individuals. We do not discount the modest transcriptional changes in proapoptotic gene products observed in our screen, since some of these genes are known mediators of death in the setting of viral infections and type I interferon signaling (12a, 74a). However, our results suggest that bystander death by apoptosis of activated CD4 ϩ T cells in HIV ϩ individuals likely occurs at later stages of activation.
It has also been reported that CD4 ϩ T cells from viremic HIV ϩ individuals exhibit cell cycle dysregulation, which resolves upon treatment with HAART (11, 57) . Similarly, cell cycle dysregulation has been observed in CD4
ϩ T cells of SIV-infected rhesus macaques (an AIDS-susceptible primate species), the degree of which correlates with immune activation and T-cell apoptosis, while cell cycle dysregulation is not observed in the CD4 ϩ T cells of SIV-infected sooty mangabeys (a natural host of SIV) (58) . Because these reports are based on correlative studies of the cell cycle markers that are confounded by focus on total CD4 ϩ T-cell populations, it is difficult to compare these results to those of the present study. Here, we used a direct experimental approach with flow cytometry to visualize simultaneously the temporal expression patterns of cyclins A and B 1 in specific activated subsets (CD25 ϩ or HLA-DR ϩ ) of CD4 ϩ T cells and found no difference between the temporal expression patterns of cyclins A and B 1 in activated CD4 ϩ T cells from untreated, viremic HIV ϩ individuals and those of cells from HIV Ϫ individuals or of PHA-activated CD4 ϩ T cells. Our finding that activated CD4 ϩ T cells are under the influence of type I interferons in the setting of HIV-1 infection is consistent with findings of previous studies documenting type I interferon effects in CD4 ϩ T cells from the secondary lymphoid tissues of HIV ϩ individuals (5, 32, 35, 44, 53, 81) . However, we extend these previous studies by specifically studying the subset of activated (CD25 ϩ ) CD4 ϩ T cells from HIV ϩ T-cell response (27) but may also impart strong proliferative and survival signals to CD4 ϩ T cells (46, 47) . Furthermore, type I interferons enhance in vitro and in vivo T H 1 effector differentiation through various direct and indirect mechanisms, including up-regulation of the IL-12 receptor and T-bet (60, 64, 73) , which is consistent with our observation that IL-12 receptor beta chain 2 and the T H 1-specific TF T-bet are up-regulated in activated CD4 ϩ T cells from HIV ϩ individuals compared to expression in cells from HIV Ϫ individuals. In the context of these in vivo studies, our results suggest that type I interferons may be responsible for many of the major differences in gene expression (e.g., upregulation of cell cycle-related and interferon-stimulated transcripts) between activated CD4 ϩ T cells from HIV ϩ individuals and those from HIV Ϫ individuals. Based on our findings and previously published reports on CD4 ϩ T-cell dynamics, we propose a model for the role of chronic CD4
ϩ T-cell activation in HIV-1-mediated CD4 ϩ Tcell depletion and the development of AIDS. Recent studies have shown that CD4 ϩ T cells differentiate along a branching, rather than linear, pathway from the naive to effector to memory states (12, 68, 78) . The process of activation and subsequent proliferation leads to asymmetric production of longlived memory cells and short-lived effector cells. In this way, normal CD4 ϩ T-cell dynamics maintain a roughly steady-state level of naive, memory, and effector cells in healthy individuals (Fig. 7A) . Furthermore, consistent with our transcriptional profiling, type I interferons may affect this steady state by shifting the balance toward T H 1 effectors (42) through upregulation of IL-12RB2 (33) , which also leads to subsequent up-regulation of T-bet by enhancing sensitivity to IL-12. In the context of this straightforward model of CD4 ϩ T-cell dynamics, it is easy to see how type I interferons could decrease the steady-state number of CD4 ϩ T cells by shifting a greater fraction of activated cells to the short-lived effector compartment (Fig. 7B) in the setting of HIV-1 infection, we believe that our model may describe a primary mechanism for CD4 ϩ T-cell depletion in chronic infection, as supported by the findings that the frequency of infected CD4 ϩ T cells in both peripheral blood and the lymphoid tissue appears to be very low during chronic HIV-1 infection (14, 20) .
This model is consistent with recent work demonstrating an increased frequency of effector CD4 ϩ T cells in the lymph nodes of untreated HIV ϩ individuals (6) . In this model, the fraction of activated CD4 ϩ T cells differentiating into shortlived effectors (reflected by the number of activated CD4 ϩ T cells) governs the degree of CD4 ϩ T-cell depletion, since an increase in this parameter pushes a larger fraction of CD4 ϩ T cells toward the short-lived effector phenotype rather than the long-lived memory phenotype. Furthermore, because the vast majority of activated CD4 ϩ T cells in HIV ϩ individuals are not HIV-1 antigen specific (19, 25) , this model demonstrates how type I interferons could cause an expansion of short-lived activated CD4 ϩ T cells independently of HIV-1 antigens. During chronic HIV-1 infection, the steady-state number of CD4 ϩ T cells may gradually decrease as increasing levels of type I interferons drive more activated CD4 ϩ T cells toward effector differentiation (43, 74) . In the setting of HAART, when there is significantly less viral antigen, the rate at which activated CD4 ϩ T cells differentiate into effector cells is lower and likely does not increase with time. Therefore, the CD4 ϩ T-cell count reaches a steady-state level that depends on the degree of local type I interferon secretion and fibrosis of lymph nodes, preventing repopulation by CD4 ϩ T cells (66, 67) . Interestingly, type I interferons are secreted in response to many viral infections that do not cause CD4 ϩ T-cell depletion.
We propose that the main difference between the beneficial effects of type I interferons during other viral infections and the potentially harmful effects of type I interferons in the setting of HIV-1 infection lies in recruitment of plasmacytoid dendritic cells (pDCs), the major type I interferon-producing cell type, to the location of active viral replication. In the setting of HIV-1 infection, pDCs are recruited to the major sites of active viral replication which lie in the secondary lymphoid tissues (32) . At these sites, resting CD4 ϩ T cells are activated, and therefore, resting CD4 ϩ T cells going through the early stages of the activation are more likely to be exposed to and affected by higher levels of type I interferons than in other viral infections not localized in the secondary lymphoid tissues. The dominant and concentration-dependent effects of type I interferons during the early stages of T-cell activation may be the difference between other viral infections and HIV infection, where a dramatic shift in normal CD4 ϩ T-cell dynamics may be manifested as a reduced CD4 ϩ T-cell count. CD8 ϩ T cells are also activated in the secondary lymphoid tissues. However, CD8 ϩ T cells, unlike CD4 ϩ T cells, appear to have a linear pathway of differentiation (68) . This linear pathway may prevent cytokines, such as type I interferons, from skewing differentiation of activated CD8 ϩ T cells from the long-lived memory pool to the short-lived effector pool. Therefore, the differentiation pathway of CD8 ϩ T cells may render them relatively immune to depletion by type I interferons.
Finally, the T H 1 immune response against HIV-1 primarily controls viral replication by promoting a CTL response. Because our results are strongly suggestive that type I interferons may play a major role in stimulation and maintenance of the T H 1 phenotype during chronic infection, the transition to AIDS and subsequent uncontrolled viral replication may be due to the failure of the innate immune system to produce type I interferons, which is consistent with recent observations that pDCs are depleted in the lymph nodes of SIV-infected macaques with AIDS (10). This suggests that type I interferons are important for maintaining some control over viral replication.
It appears, then, that the complex interaction of a greaterthan-normal innate response (mediated by type I interferons) and the adaptive response (mediated by CD4 ϩ and CD8 ϩ T cells) in the environment of secondary lymphoid tissues acts as a double-edged sword that both controls viremia and causes CD4 ϩ T-cell depletion. Therefore, we suggest that CD4 ϩ Tcell depletion during chronic and end-stage (AIDS) HIV-1 infection are mediated by two separate mechanisms that may be linked by the actions of type I interferons. In the case of chronic infection, CD4
ϩ T-cell depletion occurs as a result of preferential differentiation of CD4 ϩ T cells under the influence of type I interferons into short-lived effectors. CD4 ϩ T-cell depletion during end-stage HIV-1 infection and AIDS is a consequence of the failure of type I interferon action on CD4 ϩ and CD8 ϩ T cells (from either decreased pDCs or perhaps even decreased T-cell responsiveness), resulting in a loss of effective control of viral replication. There remain, however, several unanswered questions. In particular, what is the mechanism that slowly increases type I interferon secretion and thus drives down the CD4 ϩ T-cell count during chronic infection (e.g., viral evolution [80] or microbial translocation across compromised mucosal barriers [8] )? Also, what is the mechanism for type I interferon failure that would mark the dramatic changes observed during the transition from chronic HIV-1 infection to AIDS (e.g., T-cell exhaustion/senescence [3, 28] or depletion of pDCs [10] )? We hope that future work can be directed at modulating these mechanisms for therapeutic applications.
